Navigation Links
Breakthrough in understanding type-2 diabetes as key genes identified

The most important genes associated with a risk of developing type-2 diabetes have been identified, scientists report today in a new study.

The research, published online in Nature, is the first time the genetic makeup of any disease has been mapped in such detail. It should enable scientists to develop a genetic test to show an individual their likelihood of developing diabetes mellitus type 2, commonly known as type-2 diabetes.

The researchers identified four loci, or points on individuals' genetic maps, which corresponded to a risk of developing the disorder. The scientists, from Imperial College London, McGill University, Canada, and other international institutions, believe their findings explain up to 70% of the genetic background of type-2 diabetes.

In addition, one of the genetic mutations which they detected might further explain the causes behind type-2 diabetes, potentially leading to new treatments. The research revealed that people with type-2 diabetes have a mutation in a particular zinc transporter known as SLC30A8, which is involved in regulating insulin secretion. Type-2 diabetes is associated with a deficiency in insulin and the researchers believe it may be possible to treat it by fixing this transporter.

Professor Philippe Froguel, one of the authors of the study from the Division of Medicine at Imperial College London, said: "The two major reasons why people develop type-2 diabetes are obesity and a family link. Our new findings mean that we can create a good genetic test to predict people's risk of developing this type of diabetes.

"If we can tell someone that their genetics mean they are pre-disposed towards type-2 diabetes, they will be much more motivated to change things such as their diet to reduce their chances of developing the disorder. We can also use what we know about the specific genetic mutations associated with type-2 diabetes to develop better treatments."

The scientis ts reached their conclusions after comparing the genetic makeup of 700 people with type-2 diabetes and a family history of the condition, with 700 controls. They looked at mutations in the building blocks, called nucleotides, which make up DNA.

There are mutations in around one in every 600 nucleotides and the scientists examined over 392,000 of these mutations to find the ones specific to type-2 diabetes. The mutations are known as single-nucleotide polymorphisms.

The researchers confirmed their findings by analysing the genetic makeup of a further 5,000 individuals with type-2 diabetes and a family history of the disorder, to verify that the same genetic mutations were visible in these individuals.

Professor David Balding, co-author on the study from Imperial's Division of Epidemiology, Public Health and Primary Care, said: "Until now, progress in understanding how genes influence disease has been painfully slow. This study is one of the first large studies to report results using the new genome-wide technology that governments and research charities have invested heavily in during the past few years.

"Our research shows that this technology can generate big leaps forward. The task now is to study the genes identified in our work more intensively, to understand more fully the disease processes involved, devise therapies for those affected and to try to prevent future cases," he added.


'"/>

Source:Imperial College London


Related biology news :

1. Breakthrough Microarray-based Technology for the Study of Cancer
2. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
3. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
4. Breakthrough isolating embryo-quality stem cells from blood
5. Breakthrough System for Understanding Ocean Plant Life Announced
6. Breakthrough: Scientists create worlds tiniest organic particles
7. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
8. Sciences Breakthrough of the Year: Watching evolution in action
9. Breakthrough for stem cell research
10. Breakthrough vaccine to treat chemo-resistant ovarian cancer
11. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: